Jianlin Xu

2.4k total citations
99 papers, 1.7k citations indexed

About

Jianlin Xu is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Jianlin Xu has authored 99 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Pulmonary and Respiratory Medicine, 61 papers in Oncology and 19 papers in Molecular Biology. Recurrent topics in Jianlin Xu's work include Lung Cancer Treatments and Mutations (53 papers), Lung Cancer Research Studies (48 papers) and Lung Cancer Diagnosis and Treatment (29 papers). Jianlin Xu is often cited by papers focused on Lung Cancer Treatments and Mutations (53 papers), Lung Cancer Research Studies (48 papers) and Lung Cancer Diagnosis and Treatment (29 papers). Jianlin Xu collaborates with scholars based in China, Switzerland and United States. Jianlin Xu's co-authors include Baohui Han, Yanwei Zhang, Yuqing Lou, Hua Zhong, Runbo Zhong, Xueyan Zhang, Bo Jin, Zhi‐Yun Jiang, Tianqing Chu and Haitang Yang and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Scientific Reports.

In The Last Decade

Jianlin Xu

95 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jianlin Xu China 22 935 912 453 316 197 99 1.7k
Ramon Andrade de Mello Portugal 21 565 0.6× 745 0.8× 477 1.1× 314 1.0× 145 0.7× 89 1.4k
Guanghui Gao China 30 1.4k 1.5× 1.5k 1.6× 811 1.8× 620 2.0× 152 0.8× 86 2.5k
Apar Pataer United States 18 876 0.9× 715 0.8× 293 0.6× 178 0.6× 217 1.1× 32 1.4k
Chiara Ciccarese Italy 23 1.1k 1.2× 803 0.9× 863 1.9× 681 2.2× 421 2.1× 116 2.1k
Yasuo Ejima Japan 20 394 0.4× 379 0.4× 332 0.7× 215 0.7× 205 1.0× 49 1.3k
Jiuda Zhao China 17 573 0.6× 764 0.8× 337 0.7× 274 0.9× 214 1.1× 88 1.3k
Maria Matsangou United States 16 419 0.4× 804 0.9× 631 1.4× 248 0.8× 703 3.6× 42 1.8k
Zhenfa Zhang China 20 464 0.5× 411 0.5× 461 1.0× 319 1.0× 103 0.5× 90 1.2k
Yoshiyasu Nakamura Japan 25 398 0.4× 528 0.6× 650 1.4× 325 1.0× 203 1.0× 71 1.6k

Countries citing papers authored by Jianlin Xu

Since Specialization
Citations

This map shows the geographic impact of Jianlin Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jianlin Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jianlin Xu more than expected).

Fields of papers citing papers by Jianlin Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jianlin Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jianlin Xu. The network helps show where Jianlin Xu may publish in the future.

Co-authorship network of co-authors of Jianlin Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Jianlin Xu. A scholar is included among the top collaborators of Jianlin Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jianlin Xu. Jianlin Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Li, Jianhong, Jing Xu, Jinxia Hu, et al.. (2025). PPARγ/β/δ Agonists Can Ameliorate Dextran Sodium Sulfate–Induced Colitis and Modulate Gut Microbiota. Journal of Gastroenterology and Hepatology. 40(6). 1536–1547. 3 indexed citations
2.
Yang, Haitang, Sean R. R. Hall, Gang Liu, et al.. (2025). Transitional CXCL14+ cancer‐associated fibroblasts enhance tumour metastasis and confer resistance to EGFR‐TKIs, revealing therapeutic vulnerability to filgotinib in lung adenocarcinoma. Clinical and Translational Medicine. 15(4). e70281–e70281. 5 indexed citations
3.
Zhu, Xiaojun, Xiaodong Li, Lu Liu, et al.. (2025). Mechanisms of milk fat globule membranes to alleviate acute colitis and aging by regulating intestinal flora and intestinal barrier. Food Bioscience. 68. 106715–106715. 1 indexed citations
4.
Xu, Jing, Jianhong Li, Chen-Tsung Huang, et al.. (2025). Secondary Bile Acids Modified by Odoribacter Splanchnicus Alleviate Colitis by Suppressing Neutrophil Extracellular Trap Formation. Advanced Science. 12(46). e09073–e09073.
5.
Zheng, Liang, Fang Hu, Lin Huang, et al.. (2024). Association of metabolomics with PD-1 inhibitor plus chemotherapy outcomes in patients with advanced non-small-cell lung cancer. Journal for ImmunoTherapy of Cancer. 12(4). e008190–e008190. 6 indexed citations
6.
7.
8.
Xu, Jianlin, Shuyuan Wang, Runbo Zhong, et al.. (2023). On-treatment lung immune prognostic index is predictive for first-line PD-1 inhibitor combined with chemotherapy in patients with non-small cell lung cancer. Frontiers in Immunology. 14. 1173025–1173025. 3 indexed citations
9.
10.
Hu, Yaohua, Jianlin Xu, Rong Qiao, et al.. (2023). Multi‐target angiogenesis inhibitor combined with PD‐1 inhibitors may benefit advanced non‐small cell lung cancer patients in late line after failure of EGFR‐TKI therapy. International Journal of Cancer. 153(3). 635–643. 21 indexed citations
11.
Zhang, Yao, Haozhe Huang, Shuhui Cao, et al.. (2021). Clinical value of an electromagnetic navigation system for CT-guided percutaneous lung biopsy of peripheral lung lesions. Journal of Thoracic Disease. 13(8). 4885–4893. 8 indexed citations
12.
Xu, Jianlin, Rong Qiao, Yizhuo Zhao, et al.. (2020). Detection of Genetic Mutations by Next-Generation Sequencing for Predicting Prognosis of Extensive-Stage Small-Cell Lung Cancer. Journal of Oncology. 2020. 1–7. 6 indexed citations
13.
14.
Wang, Shuyuan, Jianlin Xu, Rui Wang, et al.. (2018). Adjuvant chemotherapy may improve prognosis after resection of stage I lung cancer with lymphovascular invasion. Journal of Thoracic and Cardiovascular Surgery. 156(5). 2006–2015.e2. 22 indexed citations
15.
Xu, Jianlin, Shun Wang, Yu Zhang, et al.. (2018). Characteristics and outcome of small cell lung cancer patients (SCLC) transformed from adenocarcinoma after tyrosine kinase inhibitor treatment. Annals of Oncology. 29. ix157–ix157. 1 indexed citations
16.
Zhang, Yanwei, Jianlin Xu, Yuqing Lou, et al.. (2016). Pretreatment direct bilirubin and total cholesterol are significant predictors of overall survival in advanced non‐small‐cell lung cancer patients with EGFR mutations. International Journal of Cancer. 140(7). 1645–1652. 36 indexed citations
17.
Xu, Jianlin, Xueyan Zhang, Bo Jin, et al.. (2016). The EGFR tyrosine kinase inhibitors as second-line therapy for EGFR wild-type non-small-cell lung cancer: a real-world study in People's Republic of China. OncoTargets and Therapy. Volume 9. 6479–6484. 3 indexed citations
18.
Xu, Jianlin, Yanwei Zhang, Bo Jin, et al.. (2016). Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations in China. Journal of Cancer Research and Clinical Oncology. 142(6). 1325–1330. 17 indexed citations
19.
Cheng, Yan, et al.. (2012). Circulating autoantibody to ABCC3 may be a potential biomarker for esophageal squamous cell carcinoma. Clinical & Translational Oncology. 15(5). 398–402. 17 indexed citations
20.
Yuan, Bin, et al.. (2012). Continuous Low-Dose-Rate Radiation of Radionuclide Phosphorus-32 for Hemangiomas. Cancer Biotherapy and Radiopharmaceuticals. 27(3). 198–203. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ramon Andrade de Mello Breakdown of academic impact, for papers by Guanghui Gao Breakdown of academic impact, for papers by Apar Pataer Breakdown of academic impact, for papers by Chiara Ciccarese Breakdown of academic impact, for papers by Yasuo Ejima Breakdown of academic impact, for papers by Jiuda Zhao Breakdown of academic impact, for papers by Maria Matsangou Breakdown of academic impact, for papers by Zhenfa Zhang Breakdown of academic impact, for papers by Yoshiyasu Nakamura
Rankless by CCL
2026